Thymalin Research

Thymalin is the only extract among the sixteen products commonly grouped as Khavinson peptide bioregulators. The other fifteen are synthetic peptides of defined sequence, though for several of them the published record leaves the exact molecule unsettled. This page is not guidance for use in people.

Research-grade Thymalin is supplied for laboratory research use only.

Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology developed Thymalin, hold patents across this family, and sell the products. They are also authors on nearly every positive finding below.

What Thymalin is

Thymalin is a polypeptide complex isolated from calf thymus ^[1][2]. Reference ^[2] attributes mild acid extraction to natural thymic factors as a class, and not to Thymalin specifically. It has no single sequence, no molecular formula and no PubChem record, its composition is not fully characterized, and its batch consistency is not documented. Reference ^[2] is not external work either, because Khavinson and colleagues from his own institute are among its authors.

A PubChem name lookup on "Thymalin" returns CID 3085284, which is thymulin, a different nonapeptide, so anyone resolving the structure that way gets the wrong molecule ^[3]. The NLM supplementary concept record for Thymalin carries a registry number but no molecular formula ^[3].

One developer-group paper describes the dipeptides KE and EW as active substances of Thymalin ^[4]. The literature does not quantify how much either contributes, and it does not establish that Thymalin's reported effects are attributable to them.

Because Thymalin is an extract, its results do not transfer to the defined synthetic peptides sold alongside it.

The COVID-19 trial

The strongest human study in this family is a randomized, single-blind, placebo-controlled trial of Thymalin in severe COVID-19 ^[5]. That ranking reflects the weakness of the surrounding literature. It ran at one hospital in Chita, Russia, with 80 patients, 36 on Thymalin and 44 on placebo.

Endpoint structure matters here, because the number that is usually quoted from this trial was not one of its primary endpoints. The trial named three primary efficacy endpoints, of which two failed: percentage of clinical improvement, time to clinical improvement, and CT imaging improvement at day 14. The day-14 CT endpoint failed, at 30.5 percent improvement versus 22.7 percent, p = 0.43. Time to clinical improvement also failed, and it ran numerically against Thymalin, at 8.63 days versus 7.61 days on placebo, p = 0.41. Percentage of clinical improvement was the one primary endpoint that reached significance, at 80.5 percent versus 59 percent, p = 0.039.

In-hospital mortality, which is the figure usually quoted, was a secondary endpoint, at 19.4 percent against 40.9 percent, p = 0.039.

This was a single center trial of 80 people, single-blind rather than double-blind, and group sizes were unbalanced after randomization with no stated explanation. The paper does apply a Hommel correction to its laboratory comparisons, but it states no testing plan across the three primary endpoints, and the outcome p-values carry no correction. No registration exists on ClinicalTrials.gov, the report is not indexed in MEDLINE, and Khavinson is second author on a paper that declares no conflict of interest. Thymalin was given by injection in the trial, not by mouth.

A 2022 paper from the same group again reported lower hospital mortality with Thymalin ^[6]. It is a retrospective analysis rather than a randomized trial. Its standard-therapy mortality figure is identical to the 2021 control arm, so the two reports appear to share that control cohort rather than to replicate one another.

The older human literature

The family's flagship longevity claim rests on a single paper from the originating group. Khavinson and Morozov followed 266 elderly people for six to eight years, reporting mortality 2.0 to 2.1 fold lower with Thymalin ^[7]. PubMed tags it a randomized controlled trial, yet the abstract gives no randomization method, no blinding and no group sizes. The same dataset appeared in Russian a year earlier ^[8], so anyone citing two studies is citing one.

Thymalin also carries a large Soviet and post-Soviet clinical literature: a burns series ^[9] and an 18-patient pancreatitis report with no control arm ^[10]. Most of that body of work is uncontrolled, and it is readable in English only as abstracts. Decades of use in one health system is a fact about practice, not about evidence quality.

A 154-patient tuberculosis trial ^[11] indexes both thymalin and glutoxim, and never states which agent went to which arm. For that reason its result cannot be attributed to Thymalin.

Laboratory and animal findings

In vitro, Thymalin changed surface marker expression on human hematopoietic stem cells, and the authors called their own inference about T cells indirect ^[1]. A second in vitro study reported reduced release of IL-1 beta, IL-6 and TNF alpha from stimulated human blood cells ^[4]. Neither result is a clinical outcome in a person.

Two animal findings run the other way, and both are nulls on lifespan. In leukemic mice, repeated Thymalin injection held lymphocyte counts near control levels but did not increase lifespan ^[12]. In rats, a synthetic dipeptide originally isolated from Thymalin left mean lifespan unchanged ^[13]. That dipeptide is not Thymalin itself.

What has not been established

There are no human pharmacokinetic data for Thymalin and no published toxicology package. A toxicology search across this family returns one 1993 record on a different question ^[14]. Absence of published toxicology is not evidence of safety. Thymalin is a bovine tissue product, and sourcing, batch variability and composition are nowhere addressed in the published record.

Regulatory status and independence

The literature reports Thymalin as registered in Russia under LS-000267, dated 26 February 2010 ^[5]. National registration confers no status in the United States, the European Union, the United Kingdom, Canada or Australia. In February 2024 the FDA issued a warning letter naming a firm's Thymalin product an unapproved new drug and a misbranded drug ^[15]. FDA added that the "research chemicals only" and "not for human consumption" labelling did not change that, because the firm's own website made the intended use plain ^[15]. No Thymalin study of any kind is registered on ClinicalTrials.gov ^[16].

Khavinson is an author on 496 PubMed records, about 65 percent in Russian, with 42 percent in two journals ^[17]. Thymalin's own name returns 234 records, 202 of them Russian, peaking in the 1980s and 1990s and falling to 17 since 2010 ^[17]. That older work is Soviet-era clinical reporting, not external validation.

What the record supports

On the published record, Thymalin is an undefined bovine tissue extract supported by one small randomized trial and a larger body of uncontrolled clinical reporting. That trial is the strongest item in this family, and two of its three primary endpoints failed. Almost every positive result comes from the group that developed, patented and sells the preparation, and this page can identify no independent replication.

Frequently Asked Questions

Is there human evidence for Thymalin? Yes, but it is thin and almost entirely from one research network. The strongest study is a randomized trial of 80 COVID-19 patients, in which two of the three primary endpoints failed and the widely quoted mortality result was secondary ^[5]. The older 266-person mortality report gives no randomization method, no blinding and no group sizes ^[7].

Is Thymalin the same thing as thymulin? No. Thymalin is an undefined polypeptide complex extracted from calf thymus, with no single sequence and no molecular formula ^[1][2]. Thymulin is a defined nonapeptide, and a PubChem name lookup on "Thymalin" returns the thymulin record instead ^[3].

Has any Thymalin finding been independently replicated? Not that this page can identify. The 2022 report shares its control mortality figure with the 2021 trial, so it is not a replication ^[5][6]. The large older Thymalin literature is Soviet-era clinical work from the same health system, not external validation ^[17].

Is Thymalin approved anywhere? The literature reports a Russian registration under LS-000267 dated 26 February 2010 ^[5]. That confers no status in the United States, the European Union, the United Kingdom, Canada or Australia. The FDA has issued a warning letter naming a firm's Thymalin product an unapproved new drug and a misbranded drug ^[15].

References

1. 1

   Khavinson VK, et al. Bulletin of Experimental Biology and Medicine, 2020;170(1):118-122. PMID 33237528. DOI 10.1007/s10517-020-05016-z.
2. 2

   Avolio F, et al. International Journal of Molecular Sciences, 2022;23(7):3607. PMID 35408963. DOI 10.3390/ijms23073607. Khavinson and St Petersburg institute colleagues are co-authors.
3. 3

   PubChem CID 3085284 (thymulin / nonathymulin) and NLM MeSH supplementary concept C032805 (thymalin). Database records queried 27 August 2026. No PMID or DOI applies.
4. 4

   Linkova N, et al. International Journal of Molecular Sciences, 2023;24(17):13377. PMID 37686182. DOI 10.3390/ijms241713377.
5. 5

   Kuznik BI, Khavinson VK, et al. Advances in Gerontology, 2021;11(4):368-376. DOI 10.1134/S2079057021040068. PMCID PMC8654498. No PMID; not indexed in MEDLINE.
6. 6

   Kuznik BI, et al. Advances in Gerontology (Uspekhi Gerontologii), 2022;35(3):368-374. PMID 36169363. Russian language, English abstract.
7. 7

   Khavinson VKh, Morozov VG. Neuroendocrinology Letters, 2003;24(3-4):233-240. PMID 14523363. No DOI assigned.
8. 8

   Khavinson VKh, Morozov VG. Uspekhi Gerontologii / Advances in Gerontology, 2002;10:74-84. PMID 12577695. Russian language, English abstract.
9. 9

   Kuznik BI, et al. Vestnik Khirurgii imeni I. I. Grekova, 2000;159(5):39-43. PMID 11188814. Russian language, English abstract.
10. 10

    Kopchak VM, et al. Klinichna Khirurhiia, 2004;(9):5-7. PMID 15560588. Ukrainian language, English abstract.
11. 11

    Maslennikov AA, et al. Problemy Tuberkuleza i Bolezney Legkikh, 2007;(9):30-33. PMID 18038603. Russian language, English abstract.
12. 12

    Potapov IuN, et al. Izvestiia Akademii Nauk SSSR, Seriia Biologicheskaia, 1991;(1):133-135. PMID 1856357. Russian language, English abstract.
13. 13

    Anisimov VN, et al. Biogerontology, 2000;1(1):55-59. PMID 11707921. DOI 10.1023/a:1010042008969.
14. 14

    Potapov IuN, et al. Izvestiia Akademii Nauk, Seriia Biologicheskaia, 1993;(3):465-468. PMID 8518725. Russian language, English abstract.
15. 15

    US Food and Drug Administration, CDER. Warning letter to US Chem Labs, MARCS-CMS 669074, 7 February 2024, signed CAPT Tina Smith. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024
16. 16

    ClinicalTrials.gov API v2 query for "thymalin", run 27 August 2026. Zero registered studies. Registry query, no PMID or DOI.
17. 17

    PubMed E-utilities corpus analysis, re-run 27 August 2026. Khavinson author record 496 items, 321 of them Russian language; thymalin[tiab] 234 records with per-decade tally. Reproducible query, no PMID or DOI.